Skip to Main Content

Uniqure, the Dutch gene therapy company, said Monday that its one-time treatment for hemophilia B was not responsible for a previously reported case of liver cancer that put the program on clinical hold.

Findings from the investigation, conducted by an independent lab, were submitted to the Food and Drug Administration last week along with a request to restart the program, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED